

### **Astellas Pharma Announces Launch of Quattrovac® for Subcutaneous Injection Syringe, Adsorbed Purified Pertussis Diphtheria Tetanus Inactivated Poliomyelitis (Sabin strain) Combined Vaccine**

Tokyo, October 30, 2012 - [Astellas Pharma Inc.](#) (“Astellas Pharma”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) today announced that its combined vaccine for the prevention of pertussis, diphtheria, tetanus, and poliomyelitis (brand name: “Quattrovac® subcutaneous injection syringe”) manufactured by the Chemo-Sero-Therapeutic Research Institute (“KAKETSUKEN”, Kumamoto, Director General: Seiji Miyamoto) will become available in the Japanese market on October 31, 2012.

The vaccine is made by combining the bulk materials of KAKETSUKEN’s Adsorbed Purified Pertussis Diphtheria Tetanus Combined Vaccine (DPT vaccine) with the bulk of inactivated poliomyelitis vaccine derived from purified attenuated polio viruses (Sabin type 1, 2, and 3) cultured in Vero cells (a cell-line derived from African Green Monkey kidney cells) made by the Japan Poliomyelitis Research Institute (JPRI). A marketing authorization has been approved for the first time in Japan in July 2012. Results showing efficacy in the prevention of pertussis, diphtheria, tetanus, and poliomyelitis and safety were obtained in clinical trials with 0.5ml subcutaneous injections per dose to children 3 months old or older but under 90 months old under the same vaccination schedule as the existing DPT vaccines.

The vaccine is manufactured at KAKETSUKEN. Astellas Pharma will conduct national sales and promotional activities similarly to its other vaccine and blood plasma products. Both companies will conduct joint sales promotion in the Kyushu area (Including Okinawa Prefecture). Upon the launch of Quattrovac, Astellas will not revise its financial forecast for the current fiscal year (from April 1, 2012 to March 31, 2013).

Astellas Pharma strive for consistent contributions towards the promotion of public health and prevention of infectious diseases.

###

## PRODUCT SUMMARY

Product name:	Quattrovac® for subcutaneous injection syringe
Generic name:	Minimum requirements for biological products: Adsorbed Purified Pertussis-Diphtheria-Tetanus-Inactivated Poliomyelitis (Sabin strain) Combined Vaccine
Indication:	Prevention of pertussis, diphtheria, tetanus, and poliomyelitis
Dosage regimen	Primary series immunization: Three subcutaneous injections of 0.5 mL per injection at intervals of 3 weeks or more Booster: One subcutaneous injection of 0.5 mL at 6 months or more after the primary series immunization
Sales commencement date:	31 October, 2012 (Plan)

For inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3201, FAX:+81-3-5201-7473 <a href="http://www.astellas.com/en">http://www.astellas.com/en</a>